BCX10013
/ BioCryst
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 08, 2025
Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
(clinicaltrials.gov)
- P1 | N=8 | Completed | Sponsor: BioCryst Pharmaceuticals | Active, not recruiting ➔ Completed
Trial completion • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases
November 25, 2024
Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
(clinicaltrials.gov)
- P1 | N=8 | Active, not recruiting | Sponsor: BioCryst Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=15 ➔ 8 | Trial completion date: Aug 2024 ➔ Dec 2024 | Trial primary completion date: Aug 2024 ➔ Dec 2024
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases
October 25, 2023
Dose Escalation of BCX10013 in Subjects With Paroxysmal Nocturnal Hemoglobinuria
(clinicaltrials.gov)
- P1 | N=15 | Recruiting | Sponsor: BioCryst Pharmaceuticals
New P1 trial • Complement-mediated Rare Disorders • Hematological Disorders • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases
1 to 3
Of
3
Go to page
1